Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Human Pathology|August 23, 2015
Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practiceArnaud Uguen, Paul Guéguen, Delphine Legoupil, et al.
Frontiers in Immunology|March 13, 2026
18F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitorsKarim Amrane, Coline Le Meur, David Bourhis, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS)Théo Erard, Gaelle Quéreux, Mona Amini-Adle, et al.
Acta Dermato-Venereologica|December 13, 2024
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre StudyLucille Vitek, Thomas Goronflot, Caroline Dutriaux, et al.
JCO Precision Oncology|November 10, 2022
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, Stéphane Dalle, Laurent Mortier, et al.
Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.
Cancers|September 9, 2022
Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter StudyLuc Ollivier, Charles Orione, Paul Bore, et al.
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Pageof 4